Project Grant R43AG085863
Award Date
9/25/24
Completion Date
8/31/25
Dollars Obligated
$505K
Federal Agency
National Institute on Aging
Awardee
Aphios Corp (HDE2J1H521A7)
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Woburn, MA 01801, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $295,000 to Florida International University (FIU) to develop and test a novel nanogel system for the treatment of Alzheimer's disease (AD). The proposed nanogels are designed to cross the blood-brain barrier and target key biomarkers of AD, including amyloid-beta (Aβ) aggregation, neuroinflammation, and oxidative stress. This project aims to improve the nanogel's ability to transmigrate...
This Project Grant award from the National Institute on Aging (NIA), under CFDA 93.866 Aging Research, provides $2,432,649 to Virogenics, Inc., a biotechnology company in San Diego, California, to advance the development of their novel Alzheimer's disease drug candidate, CMS121. The funding will support two critical components: 1) a 13-week toxicology study in rats and dogs to enable longer-term clinical trials of CMS121 in human patients with mild to moderate Alzheimer's disease, and 2) the...
This $506,451 Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) supports the development of a targeted exosomal delivery system for small interfering RNA (siRNA) therapeutics to mitigate neuroinflammatory diseases, including Alzheimer's disease. The primary recipient, 3P Biotechnologies, Inc., will optimize the delivery of siRNA targeting NF-kB using folic acid-functionalized exosomes and a novel trans-spinal administration route. This innovative approach aims...
This Project Grant award of $500,000 was provided by the National Institute on Aging (CFDA 93.866 Aging Research) to Alzarrok Bio LLC to develop a peptide-based multitarget drug for Alzheimer's disease. The project aims to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an Alzheimer's disease mouse model. Key activities include measuring drug concentrations in the brain and blood, evaluating the drug's impact on target...
This Project Grant award from the National Institute on Aging (part of the National Institutes of Health, CFDA# 93.866 Aging Research) provides $1,041,646 to Cenna Biosciences Inc. to support early clinical development of a novel peptide drug candidate, modified P8 (MP8), for the treatment of Alzheimer's disease. The funding will be used to conduct chemistry, manufacturing, and controls (CMC) activities to prepare for a first-in-human clinical study, hold a pre-IND meeting with the FDA, submit...
This $499,968 Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) supports the development of novel, potent, and selective Kv1.3 potassium channel inhibitors as potential therapeutics for Alzheimer's disease. The awardee, Hager Biosciences, LLC, aims to further characterize and optimize lead compounds that have demonstrated efficacy in inhibiting Kv1.3 channels, which play a key role in neuroinflammatory processes associated with...
This federal Project Grant award of $994,436 from the National Institute on Aging (CFDA 93.866 - Aging Research) to Transchromix LLC supports research to develop novel brain-penetrant drugs that target the histone methyltransferase G9A for the treatment of Alzheimer's disease. The grant funding will enable the research team to further investigate the noncanonical, translation regulatory function of G9A in Alzheimer's disease pathogenesis and evaluate the mechanism of action for the...
This Federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to demonstrate the in vitro and in vivo effectiveness of SMC-101 nanotubes as a drug delivery system to treat Alzheimer's disease and related dementias. The $949,062 award to Somatoceutics LLC will fund two specific aims: 1) optimizing and standardizing SMC-101 nanotube assembly, drug-loading, and blood-brain barrier transcytosis in vitro, and 2) evaluating the toxicity of SMC-101...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) for $445,625 supports research to develop an innovative nanotechnology approach to interrupt the inflammatory signaling pathways between glial cells that exacerbate Alzheimer's disease (AD) progression. The research aims to elucidate how scavenger receptor-targeted nanoparticles can ameliorate the pathological glial communications driven by fibrillar amyloid-beta (FAB), and evaluate the longer-term...
The National Institute on Aging (NIA) has awarded Neucyte Inc., a minority-owned small business, a $500,000 Project Grant under the Aging Research federal grant program (CFDA 93.866) to develop an innovative microphysiological systems (MPS) platform for high-throughput screening of potential Alzheimer's disease (AD) and AD-related dementia (ADRD) therapeutics. The project aims to create a "mini-brain assembled organoids" (assembloids) platform using AD patient-derived and gene-edited...